The liver's sensitive inflammation signal
High-sensitivity C-reactive protein (hs-CRP) blood testing measures the amount of C-reactive protein circulating in your bloodstream. CRP is a protein made in the liver (hepatocytes) when the immune system sends inflammatory signals, especially interleukin‑6. It is part of the acute-phase response, the body's rapid, coordinated reaction to injury or infection. The "high-sensitivity" version detects very low concentrations of CRP, allowing clinicians to pick up quiet, background inflammation that a standard CRP test would miss.
CRP helps the body's cleanup crew. It binds to damaged cell fragments and certain microbes, tagging them for removal (opsonization) and activating a defense cascade (complement). Because the liver releases CRP whenever inflammation is present anywhere in the body, its level serves as a practical barometer of overall inflammatory activity. Measured with high sensitivity, it can reflect persistent, low-grade inflammation—particularly within blood vessel walls (vascular inflammation) relevant to plaque buildup (atherosclerosis). In short, hs‑CRP offers a clear readout of your body's inflammatory tone.
A whole-body barometer of inflammatory load
High-sensitivity C‑reactive protein (hs‑CRP) is a liver-made signal that rises when the innate immune system is activated. Because it integrates inflammatory cues from blood vessels, fat tissue, the gut, and infections, it serves as a whole‑body barometer of "inflammatory load," linking immune activity to heart, metabolic, and brain health.
High-sensitivity C-reactive protein (hs-CRP) measures very low levels of C-reactive protein made by the liver in response to inflammatory signals (notably IL‑6). It is a readout of background, whole‑body inflammation that influences how blood vessels function, how energy is allocated, and how the immune system prioritizes repair. Persistently higher hs‑CRP tracks with cardiometabolic risk, endothelial stress, and can relate to cognition and reproductive signaling through shared inflammatory pathways.
Translating the 1, 3, and 10 mg/L thresholds
Typical values span very low to markedly elevated. For cardiovascular risk stratification, below about 1 is considered low risk, 1–3 average, and above 3 higher risk; values above 10 usually point to an acute process. For long‑term health, within reference ranges tends to sit toward the low end.
When hs‑CRP is low, it reflects quiet innate immunity, intact vascular lining, and low background cytokine signaling. People usually feel well, with steady energy and recovery. Very low values are generally not concerning; rarely, unexpectedly low hs‑CRP despite illness can occur with severe liver synthetic impairment or profound immune suppression.
Low values usually reflect a low inflammatory burden and well-regulated innate immunity. They are common in younger, lean, otherwise healthy people and in some genetic CRP variants. Rarely, unexpectedly low CRP despite clear illness can occur with severe liver synthetic impairment or impaired cytokine signaling.
Being in range suggests stable inflammatory tone, quieter endothelial activation, and fewer competing demands on metabolism. For cardiovascular risk assessment, consensus places "optimal" toward the lower end of the usual reference range when measured at baseline wellness, not during acute illness.
When hs‑CRP is high, the liver is responding to inflammatory signals—from infections, autoimmune flares, tissue injury, or chronic sterile inflammation in adipose tissue and vessel walls. Persistently elevated values correlate with endothelial activation, plaque formation and instability, insulin resistance, and a pro‑thrombotic state. Symptoms come from the cause (fever, soreness, fatigue), not from CRP itself. Women often run slightly higher than men; pregnancy and the postpartum period can raise levels; children typically have lower baselines except during infection.
High values usually reflect an active inflammatory state—from recent infection, tissue injury, or chronic drivers such as adipose‑derived inflammation, insulin resistance, autoimmune activity, or periodontal disease. Very high results often indicate acute infection or trauma. Baseline hs‑CRP tends to run slightly higher with aging and in many women, and rises further during pregnancy and with estrogen-containing therapies.
When to retest and what shifts the number
Interpret hs‑CRP in context; it is specific to inflammation, not to a particular disease. Values fluctuate day to day and rise with intercurrent illness, vaccinations, or strenuous exercise. Many labs recommend repeat measurements when well. Assay methods differ slightly across laboratories.
Translating invisible inflammation into risk
Big picture: hs‑CRP connects the immune and metabolic systems to cardiovascular biology. Alongside lipids, blood pressure, glucose measures, kidney markers, and lipoprotein(a), it refines risk for heart attack, stroke, and type 2 diabetes, helping translate invisible inflammation into actionable risk understanding over time.
FAQs
Testing hs-CRP reveals inflammation-related risk not captured by cholesterol or blood pressure alone, helps track lifestyle and therapy effects, and supports better training and recovery decisions.
Test when you are well and repeat to confirm new elevations. Ongoing monitoring is useful when tracking lifestyle changes, recovery patterns, or the impact of therapies on inflammation.
Infections, injuries, strenuous exercise, central adiposity, insulin resistance, poor sleep, smoking, periodontal disease, oral estrogen therapy, and pregnancy can all raise hs-CRP.
Fasting is not required. For a stable baseline, avoid heavy training for 24–48 hours and wait until fully recovered from illness or injury before testing.
High-sensitivity assays detect very low concentrations reliably. Because hs-CRP varies day to day, repeat testing improves accuracy in defining your true baseline.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Ridker, P. M. (2016). A test in context: High-sensitivity C-reactive protein. Journal of the American College of Cardiology, 67(6), 712-723. https://doi.org/10.1016/j.jacc.2015.11.037
- Ridker, P. M. (2004). High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit. American Heart Journal, 148(1 Suppl), S19-S26. https://doi.org/10.1016/j.ahj.2004.04.028
- Islam, M. M., Satici, M. O., & Eroglu, S. E. (2024). Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review. Turkish Journal of Emergency Medicine, 24(1), 8-19. https://doi.org/10.4103/tjem.tjem_198_23
- He, X., Su, A., Xu, Y., Ma, D., Yang, G., Peng, Y., Guo, J., Hu, M., & Ma, Y. (2022). Prognostic role of lymphocyte-C-reactive protein ratio in colorectal cancer: A systematic review and meta-analysis. Frontiers in Oncology, 12, 905144. https://doi.org/10.3389/fonc.2022.905144
- Brigden, M. L. (1999). Clinical utility of the erythrocyte sedimentation rate. American Family Physician, 60(5), 1443-1450. https://pubmed.ncbi.nlm.nih.gov/10524488/






































.avif)
